Biotherapies in large vessel vasculitis

被引：50

作者：

Ferfar, Y. ^{[1
]}

Mirault, T. ^{[2
]}

Desbois, A. C. ^{[1
]}

Comarmond, C. ^{[1
]}

Messas, E. ^{[2
]}

Savey, L. ^{[1
]}

Domont, F. ^{[1
]}

Cacoub, P. ^{[1
]}

Saadoun, D. ^{[1
]}

机构：

[1] Univ Paris 06, Grp Hosp Pitie Salpetriere, AP HP,Serv Med Interne & Immunol Clin,DHU I2B, Ctr Reference Malad Autoimmunes & Syst Rares,Immu, Paris, France

[2] Grp Hosp HEGP, AP HP, Serv Med Vasc, Ctr Natl Reference Malad Vasc Rares, Paris, France

来源：

AUTOIMMUNITY REVIEWS | 2016年 / 15卷 / 06期

关键词：

Giant cell arteritis; Takayasu; Behcet's disease; Relapsing polychondritis; Biotherapy; GIANT-CELL ARTERITIS; REFRACTORY TAKAYASU ARTERITIS; PLACEBO-CONTROLLED TRIAL; NECROSIS FACTOR THERAPY; ANTI-TNF-ALPHA; RELAPSING POLYCHONDRITIS; BEHCETS-DISEASE; POLYMYALGIA-RHEUMATICA; EULAR RECOMMENDATIONS; SUSTAINED RESPONSE;

D O I：

10.1016/j.autrev.2016.02.012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are large vessel vasculitis (LW) and aortic involvement is not uncommon in Behcet's disease (BD) and relapsing polychondritis (RP). Glucocorticosteroids are the mainstay of therapy in LW. However, a significant proportion of patients have glucocorticoid dependance, serious side effects or refractory disease to steroids and other immunosuppressive treatments such as cyclophosphamide, azathioprine, mycophenolate mofetil and methotrexate. Recent advances in the understanding of the pathogenesis have resulted in the use of biological agents in patients with LW. Anti-tumor necrosis factor-alpha drugs seem effective in patients with refractory Takayasu arteritis and vascular BD but have failed to do so in giant cell arteritis. Preliminary reports on the use of the anti-IL6-receptor antibody (tocilizumab), in LW have been encouraging. The development of new biologic targeted therapies will probably open a promising future for patients with LW. (C) 2016 Elsevier B.V. All rights reserved.

引用

页码：544 / 551

页数：8

共 50 条

[41] A pragmatic approach to imaging in large vessel vasculitis
Patil, Pravin
Dejaco, Christian
Dasgupta, Bhaskar
EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (07): : 767 - 775
[42] Medium and large vessel vasculitis
Clivati Brandt, Hebert Roberto
Arnone, Marcelo
Sakai Valente, Neusa Yuriko
Sotto, Mirian Nacagami
Criado, Paulo Ricardo
ANAIS BRASILEIROS DE DERMATOLOGIA, 2009, 84 (01) : 55 - 67
[43] Role of Imaging in the Diagnosis of Large and Medium-Sized Vessel Vasculitis
Pipitone, Nicolo
Versari, Annibale
Hunder, Gene G.
Salvarani, Carlo
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2013, 39 (03) : 593 - +
[44] FDG PET Imaging of Large-Vessel Vasculitis
Cao, Qi
Chen, Wengan
PET CLINICS, 2012, 7 (02) : 227 - 232
[45] Cellular Signaling Pathways in Medium and Large Vessel Vasculitis
Watanabe, Ryu
Berry, Gerald J.
Liang, David H.
Goronzy, Jorg J.
Weyand, Cornelia M.
FRONTIERS IN IMMUNOLOGY, 2020, 11
[46] Immune mechanisms in medium and large-vessel vasculitis
Weyand, Cornelia M.
Goronzy, Joerg J.
NATURE REVIEWS RHEUMATOLOGY, 2013, 9 (12) : 731 - 740
[47] Pathogenesis of medium- and large-vessel vasculitis
Weyand, C. M.
Goronzy, J. J.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2009, 68 (02): : 100 - +
[48] New treatment strategies in large-vessel vasculitis
Unizony, Sebastian
Stone, John H.
Stone, James R.
CURRENT OPINION IN RHEUMATOLOGY, 2013, 25 (01) : 3 - 9
[49] Pros and cons of TNF inhibitors and tocilizumab in the treatment of large-vessel vasculitis
Marvisi, C.
Ricordi, C.
Galli, E.
Muratore, F.
Boiardi, L.
Macchioni, P. L.
Pipitone, N.
Macaluso, F.
Salvarani, C.
Brandolino, F.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (04) : 975 - 981
[50] Rapid induction of remission in large vessel vasculitis by IL-6 blockade
Seitz, Michael
Reichenbach, Stephan
Bonel, Harald M.
Adler, Sabine
Wermelinger, Felix
Villiger, Peter M.
SWISS MEDICAL WEEKLY, 2011, 141

← 1 2 3 4 5 →